Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting
| KPRX Stock | USD 3.25 0.01 0.31% |
Slightly above 61% of Kiora Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Kiora Pharmaceuticals suggests that many traders are alarmed. Kiora Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Kiora Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Kiora |
Encinitas, California-- - Kiora Pharmaceuticals, Inc. , announced their abstract of a preclinical study of KIO-104 in a proliferative vitreoretinopathy model was accepted for poster presentation at the Association for Research in Vision and Ophthalmology meeting in Salt Lake City, UT, May 4-8, 2025. The findings support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.
Read at finance.yahoo.com
 |
Kiora Pharmaceuticals Fundamental Analysis
We analyze Kiora Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiora Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiora Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Kiora Pharmaceuticals is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Kiora Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiora Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiora Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiora Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Kiora Pharmaceuticals Related Equities
| QNRX | Quoin Pharmaceuticals | 3.45 | ||||
| BDRX | Biodexa Pharmaceticals | 1.53 | ||||
| UNCY | Unicycive Therapeutics | 1.69 | ||||
| CDIO | Cardio Diagnostics | 2.44 | ||||
| REVB | Revelation Biosciences | 3.82 | ||||
| ALLR | Allarity Therapeutics | 11.76 | ||||
| VRAX | Virax Biolabs | 12.24 | ||||
| PALI | Palisade Bio | 12.38 |
Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.